⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1446428 | 1.00 | — | — | |
| SCHEMBL1446037 | 0.84 | — | — | |
| SCHEMBL1145767 | 0.84 | — | — | |
| SCHEMBL345405 | 0.84 | — | — | |
| SCHEMBL1146049 | 0.81 | ALDH1A1 (0.35) | — | |
| SCHEMBL3907816 | 0.81 | ALDH1A1 (0.35) | — | |
| SCHEMBL11798711 | 0.73 | — | — | |
| SCHEMBL3806495 | 0.72 | CRBN (0.33) | — | |
| Methane SCHEMBL17046414 | 0.70 | — | — | |
| SCHEMBL2253322 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 363 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689659-B | Imidazooxazole derivative having anti-tumor effect and pharmaceutical composition comprising the same | 韩国科学技术研究院 | 2022-01-28 | — | — | CN | claimed |
| CN-107523015-B | Preparation method of carbon nano tube-montmorillonite self-assembly nano powder grafted glass fiber reinforced resin composite material | 河海大学 | 2020-02-18 | — | — | CN | claimed |
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-02 | — | — | US | claimed |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | claimed |
| US-8680281-B2 | Lactam inhibitors of 11-β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | claimed |
| US-8592409-B2 | Cyclic carbazate and semicarbazide inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-26 | — | — | US | claimed |
| EP-2252601-B1 | CYCLIC CARBAZATE AND SEMICARBAZIDE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2012-12-19 | — | — | EP | claimed |
| US-20110112082-A1 | CYCLIC CARBAZATE AND SEMICARBAZIDE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2011-05-12 | — | — | US | claimed |
| US-20110098320-A1 | Lactam Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. | 2011-04-28 | — | — | US | claimed |
| US-20090104116-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2009-04-23 | — | — | US | claimed |
| EP-1979342-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | Jerini AG (DE) | 2008-10-15 | — | — | EP | claimed |
| WO-2007088041-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2007-08-09 | — | — | WO | claimed |
| US-20070021429-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-01-25 | — | — | US | claimed |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | NEUROCRINE BIOSCIENCES, INC. | 2007-01-04 | — | — | US | claimed |
| CN-1805958-A | fused N-heterocyclic compounds and their use as CRF receptor antagonists | SB PHARMCO INC (PR) | 2006-07-19 | — | — | CN | claimed |
| EP-1618107-A1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SB Pharmco Puerto Rico Inc (US) | 2006-01-25 | — | — | EP | claimed |
| US-6872738-B1 | Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2005-03-29 | — | — | US | claimed |
| WO-2004094419-A1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC (US) | 2004-11-04 | — | — | WO | claimed |
| EP-1233786-B1 | PRODUCT COMPRISING AT LEAST A NO SYNTHASE INHIBITING SUBSTANCE ASSOCIATED WITH AT LEAST A PHOSPHOLIPASE A2 INHIBITING SUBSTANCE FOR THE PREPARATION OF A MEDICAMENT | CONSEILS DE RECH SET D APPLIC (FR) | 2004-02-18 | — | — | EP | claimed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4638444-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4159200-B1 | PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD | JIANGSU KANION PHARMACEUTICAL CO LTD (CN) | 2025-08-13 | — | — | EP | disclosed |
| EP-4556467-A2 | METHODS FOR ARRAY SYNTHESIS | Vibrant Holdings, LLC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12266758-B2 | Polymer electrolyte for a solid state battery | TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12251674-B2 | Substrates, systems, and methods for array synthesis and biomolecular analysis | VIBRANT HOLDINGS, LLC (US) | 2025-03-18 | — | — | US | disclosed |
| EP-3617219-B1 | METHODS FOR ARRAY SYNTHESIS | VIBRANT HOLDINGS LLC (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-119431365-A | Phenyl heterocyclic derivative-containing regulator and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119264042-A | Cyclopentane derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-114466850-B | [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine | 拜耳股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-111886224-B | Heterocyclic inhibitors of ATR kinase | 德州大学系统董事会 | 2024-07-23 | — | — | CN | disclosed |
| WO-2024137724-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-06-27 | — | — | WO | disclosed |
| US-12012467-B2 | Small molecule DCN1 inhibitors and therapeutic methods using the same | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-18 | — | — | US | disclosed |
| US-20240186564-A1 | POLYMER ELECTROLYTE FOR A SOLID STATE BATTERY | TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2024084227-A1 | SUBSTITUTED BICYCLIC DIENES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2024-04-25 | — | — | WO | disclosed |
| EP-3483166-B1 | IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | KOREA INST SCI & TECH (KR) | 2023-11-01 | — | — | EP | disclosed |
| EP-4262807-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230294064-A1 | SUBSTRATES, SYSTEMS, AND METHODS FOR NUCLEIC ACID ARRAY SYNTHESIS | VIBRANT HOLDINGS, LLC | 2023-09-21 | — | — | US | disclosed |
| EP-3713926-B1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AG (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| CN-115956101-A | Thermoplastic composition, method, device and use | 德里克公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20230072276-A1 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| US-11524944-B2 | 2-phenylpyrimidine-4-carboxamides as AHR inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-13 | — | — | US | disclosed |
| US-11459312-B2 | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-04 | — | — | US | disclosed |
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-4013508-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | Bayer Aktiengesellschaft (DE) | 2022-06-22 | — | — | EP | disclosed |
| US-11332479-B2 | Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-05-17 | — | — | US | disclosed |
| CN-114466850-A | [1,2,4] triazolo [1,5-C ] quinazolin-5-amines | 拜耳股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-11304946-B2 | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2022-04-19 | — | — | US | disclosed |
| EP-3609876-B1 | COVALENT SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-109476668-B | 6, 7-dihydro-4H-pyrazolo [1,5-a ] pyrazines and 6, 7-dihydro-4H-triazolo [1,5-a ] pyrazines for the treatment of infectious diseases | 豪夫迈·罗氏有限公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2022029063-A1 | PYRIDO[1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-10 | — | — | WO | disclosed |
| CN-109689659-B | Imidazooxazole derivative having anti-tumor effect and pharmaceutical composition comprising the same | 韩国科学技术研究院 | 2022-01-28 | — | — | CN | disclosed |
| CN-107674071-B | Carbazole-containing sulfonamides as cryptochrome modulators | 同步制药公司 | 2021-12-31 | — | — | CN | disclosed |
| EP-3713923-B1 | 2-PHENYLPYRIMIDINE-4-CARBOXAMIDES AS AHR INHIBITORS | BAYER AG (DE) | 2021-12-01 | — | — | EP | disclosed |
| US-20200406220-A1 | Substrates, Systems, and Methods for Array Synthesis and Biomolecular Analysis | VIBRANT HOLDINGS, LLC | 2020-12-31 | — | — | US | disclosed |
| CN-111886224-A | Heterocyclic inhibitors of ATR kinase | 德州大学系统董事会 | 2020-11-03 | — | — | CN | disclosed |
| US-20200325127-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2020-10-15 | — | — | US | disclosed |
| US-10799845-B2 | Substrates, systems, and methods for array synthesis and biomolecular analysis | VIBRANT HOLDINGS, LLC (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800774-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200299269-A1 | SULPHUR SUBSTITUTED 3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2020-09-24 | — | — | US | disclosed |
| EP-3138840-B1 | THIADIAZOLIDINE DERIVATIVE AS ANTI-ENTEROVIRUS 71 | JIANGSU KANION PHARMACEUTICAL CO LTD (CN) | 2020-09-23 | — | — | EP | disclosed |
| US-20200289509-A1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-17 | — | — | US | disclosed |
| EP-3478662-B1 | AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO5) LTD (GB) | 2020-09-16 | — | — | EP | disclosed |
| US-20200283395-A1 | 2-PHENYLPYRIMIDINE-4-CARBOXAMIDES AS AHR INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2020-09-10 | — | — | US | disclosed |
| EP-3257851-B1 | SALT FORM AND CRYSTAL FORM OF 1,2,5 THIADIAZOLIDIN-1,1-DIOXIDE, PREPARATION METHOD THEREOF AND INTERMEDIATE | JIANGSU KANION PHARMACEUTICAL CO LTD (CN) | 2020-09-09 | — | — | EP | disclosed |
| US-10730889-B2 | Amido spirocyclic amide and sulfonamide derivatives | FORMA TM, LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-10729688-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3668839-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | Board of Regents, The University of Texas System (US) | 2020-06-24 | — | — | EP | disclosed |
| CN-107406439-B | Salt form and crystal form of 1,2, 5-thiadiazolidine-1, 1-dioxide, preparation method and intermediate thereof | 江苏康缘药业股份有限公司 | 2020-06-16 | — | — | CN | disclosed |
| CN-107406439-B | Salt form and crystal form of 1,2, 5-thiadiazolidine-1, 1-dioxide, preparation method and intermediate thereof | 江苏康缘药业股份有限公司 | 2020-06-16 | — | — | CN | disclosed |
| EP-3286166-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2020-05-13 | — | — | EP | disclosed |
| US-20200109167-A1 | SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2020-04-09 | — | — | US | disclosed |
| US-10590083-B2 | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-17 | — | — | US | disclosed |
| EP-3617219-A1 | METHODS FOR ARRAY SYNTHESIS | Vibrant Holdings, LLC (US) | 2020-03-04 | — | — | EP | disclosed |
| US-10577353-B2 | 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2020-03-03 | — | — | US | disclosed |
| CN-110691821-A | Thermoplastic composition, method, apparatus and use | 德里克公司 | 2020-01-14 | — | — | CN | disclosed |
| CN-106661009-B | Anti- enteric virus71 thiadiazolidine derivative | 江苏康缘药业股份有限公司 | 2019-11-26 | — | — | CN | disclosed |
| CN-106661009-B | Anti- enteric virus71 thiadiazolidine derivative | 江苏康缘药业股份有限公司 | 2019-11-26 | — | — | CN | disclosed |
| US-20190321360-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-10-24 | — | — | US | disclosed |
| US-20190307776-A1 | AZA-SUBSTITUTED INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2019-10-10 | — | — | US | disclosed |
| WO-2019191166-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| EP-3334723-B1 | 5-(N-[6,5]-FUSED BICYCLIC ARYL TETRAHYDROISOQUINOLIN-6-YL) PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2019-09-18 | — | — | EP | disclosed |
| US-10407410-B2 | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2019-09-10 | — | — | US | disclosed |
| US-10399944-B2 | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-03 | — | — | US | disclosed |
| US-20190262794-A1 | SUBSTRATES, SYSTEMS, AND METHODS FOR NUCLEIC ACID ARRAY SYNTHESIS | VIBRANT HOLDINGS, LLC | 2019-08-29 | — | — | US | disclosed |
| EP-2920272-B1 | METHODS FOR ARRAY SYNTHESIS | VIBRANT HOLDINGS LLC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10383880-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | Synchronicity (US) | 2019-08-20 | — | — | US | disclosed |
| US-10383880-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | Synchronicity (US) | 2019-08-20 | — | — | US | disclosed |
| US-10351546-B2 | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2019-07-16 | — | — | US | disclosed |
| US-20190209550-A1 | AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-11 | — | — | US | disclosed |
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-02 | — | — | US | disclosed |
| US-20190152957-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-23 | — | — | US | disclosed |
| US-10286376-B2 | Substrates, systems, and methods for array synthesis and biomolecular analysis | VIBRANT HOLDINGS, LLC (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190135857-A1 | TRITERPENOID INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| EP-3478703-A1 | TRITERPENOID INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ViiV Healthcare UK (No.5) Limited (GB) | 2019-05-08 | — | — | EP | disclosed |
| EP-3478662-A1 | AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ViiV Healthcare UK (No.5) Limited (GB) | 2019-05-08 | — | — | EP | disclosed |
| EP-3478661-A1 | AZA-SUBSTITUTED INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ViiV Healthcare UK (No.5) Limited (GB) | 2019-05-08 | — | — | EP | disclosed |
| US-20190127351-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | disclosed |
| US-20190111404-A9 | Substrates, Systems, and Methods for Array Synthesis and Biomolecular Analysis | VIBRANT HOLDINGS, LLC | 2019-04-18 | — | — | US | disclosed |
| US-20190092754-A1 | 5-(N-BENZYL TETRAHYDROISOQUINOLIN-6-YL) PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2019-03-28 | — | — | US | disclosed |
| EP-3455215-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ViiV Healthcare UK (No.5) Limited (GB) | 2019-03-20 | — | — | EP | disclosed |
| EP-3455217-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ViiV Healthcare UK (No.5) Limited (GB) | 2019-03-20 | — | — | EP | disclosed |
| EP-3455214-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ViiV Healthcare UK (No.5) Limited (GB) | 2019-03-20 | — | — | EP | disclosed |
| US-10227339-B2 | Salt form and crystal form of 1,2,5-thiadiazolidin-1,1-dioxide, preparation method thereof and intermediate | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2019-03-12 | — | — | US | disclosed |
| US-10221156-B2 | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2019-03-05 | — | — | US | disclosed |
| US-10221129-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2019-03-05 | — | — | US | disclosed |
| US-20190055240-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
| WO-2019036641-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-02-21 | — | — | WO | disclosed |
| US-10208062-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-19 | — | — | US | disclosed |
| US-20190047959-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047961-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| US-10189816-B2 | Substituted pyridines as inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-20190010139-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2019-01-10 | — | — | US | disclosed |
| US-10138253-B2 | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2018-11-27 | — | — | US | disclosed |
| EP-3402897-A1 | SUBSTRATES, SYSTEMS, AND METHODS FOR NUCLEIC ACID ARRAY SYNTHESIS | Vibrant Holdings, LLC (US) | 2018-11-21 | — | — | EP | disclosed |
| US-10106504-B2 | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2018-10-23 | — | — | US | disclosed |
| US-20180289677-A1 | Covalent Small Molecule DCN1 Inhibitors and Therapeutic Methods Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-10-11 | — | — | US | disclosed |
| EP-3257851-A4 | SALT FORM AND CRYSTAL FORM OF 1,2,5 THIADIAZOLIDIN-1,1-DIOXIDE, PREPARATION METHOD THEREOF AND INTERMEDIATE | Jiangsu Kanion Pharmaceutical Co., Ltd. (CN) | 2018-09-19 | — | — | EP | disclosed |
| US-20180222864-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-08-09 | — | — | US | disclosed |
| US-20180222890-A1 | 5-(N-[6,5]-FUSED BICYCLIC ARYL TETRAHYDROISOQUINOLIN-6-YL) PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-08-09 | — | — | US | disclosed |
| EP-2855458-B1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2855458-B1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | RESET THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| CN-108368093-A | The pyridin-3-yl acetogenin of inhibitor as human immunodeficiency virus replication | VIIV保健英国第五有限公司 | 2018-08-03 | — | — | CN | disclosed |
| CN-108349939-A | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | VIIV保健英国第五有限公司 | 2018-07-31 | — | — | CN | disclosed |
| EP-3337798-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-27 | — | — | EP | disclosed |
| US-20180170904-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-21 | — | — | US | disclosed |
| US-20180170903-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-21 | — | — | US | disclosed |
| EP-3334716-A1 | 5-(N-BENZYL TETRAHYDROISOQUINOLIN-6-YL) PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-20 | — | — | EP | disclosed |
| EP-3334722-A1 | 5-(N-FUSED TRICYCLIC ARYL TETRAHYDROISOQUINOLIN-6-YL) PYRIDIN-3- YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-20 | — | — | EP | disclosed |
| EP-3334741-A1 | IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-20 | — | — | EP | disclosed |
| EP-3334723-A1 | 5-(N-[6,5]-FUSED BICYCLIC ARYL TETRAHYDROISOQUINOLIN-6-YL) PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-20 | — | — | EP | disclosed |
| EP-3334724-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-20 | — | — | EP | disclosed |
| US-20180162831-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-14 | — | — | US | disclosed |
| EP-3331868-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-13 | — | — | EP | disclosed |
| CN-108137532-A | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV保健英国第五有限公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-108137552-A | 5- (N- fused tricyclic aryl tetrahydroisoquinoline -6- bases) pyridin-3-yl acetogenin of inhibitor as human immunodeficiency virus replication | VIIV保健英国第五有限公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-108137534-A | 5- (N- benzyl tetrahydro isoquinoline -6- bases) pyridin-3-yl acetogenin of inhibitor as human immunodeficiency virus replication | VIIV保健英国第五有限公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-108137553-A | 5- (N- [6,5]-fused bicyclic aryl tetrahydroisoquinoline -6- bases) pyridin-3-yl acetogenin of inhibitor as human immunodeficiency virus replication | VIIV保健英国第五有限公司 | 2018-06-08 | — | — | CN | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-20180147196-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-05-31 | — | — | US | disclosed |
| US-20180141940-A1 | SALT FORM AND CRYSTAL FORM OF 1,2,5-THIADIAZOLIDIN-1,1-DIOXIDE, PREPARATION METHOD THEREOF AND INTERMEDIATE | JIANGSU KANION PARMACEUTICAL CO. LTD (CN) | 2018-05-24 | — | — | US | disclosed |
| EP-3319954-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-05-16 | — | — | EP | disclosed |
| EP-3319953-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-05-16 | — | — | EP | disclosed |
| EP-3319958-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-05-16 | — | — | EP | disclosed |
| EP-3319957-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-05-16 | — | — | EP | disclosed |
| CN-108026113-A | IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV保健英国第五有限公司 | 2018-05-11 | — | — | CN | disclosed |
| CN-107995910-A | The inhibitor of human immunodeficiency virus replication | VIIV保健英国第五有限公司 | 2018-05-04 | — | — | CN | disclosed |
| US-20180086697-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-29 | — | — | US | disclosed |
| CN-107820492-A | Pyridin-3-yl acetic acid derivatives as inhibitors of HIV replication | VIIV保健英国第五有限公司 | 2018-03-20 | — | — | CN | disclosed |
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2018-03-15 | — | — | US | disclosed |
| CN-107771177-A | The acetic acid derivatives of pyridine 3 as the inhibitor of human immunodeficiency virus replication | VIIV保健英国第五有限公司 | 2018-03-06 | — | — | CN | disclosed |
| WO-2018011100-A1 | NOVEL TETRAHYDROPYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
| WO-2018002849-A1 | TRITERPENOID INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-01-04 | — | — | WO | disclosed |
| WO-2018002848-A1 | AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-01-04 | — | — | WO | disclosed |
| WO-2018002847-A1 | AZA-SUBSTITUTED INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-01-04 | — | — | WO | disclosed |
| EP-3257851-A1 | SALT FORM AND CRYSTAL FORM OF 1,2,5 THIADIAZOLIDIN-1,1-DIOXIDE, PREPARATION METHOD THEREOF AND INTERMEDIATE | Jiangsu Kanion Pharmaceutical Co., Ltd. (CN) | 2017-12-20 | — | — | EP | disclosed |
| CN-107406439-A | Salt form and crystal form of 1,2, 5-thiadiazolidine-1, 1-dioxide, preparation method and intermediate thereof | 江苏康缘药业股份有限公司 | 2017-11-28 | — | — | CN | disclosed |
| WO-2017195111-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017195113-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017195112-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-11-16 | — | — | WO | disclosed |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-9775845-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9775845-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9775845-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170239196-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2017-08-24 | — | — | US | disclosed |
| WO-2017117292-A1 | SUBSTRATES, SYSTEMS, AND METHODS FOR NUCLEIC ACID ARRAY SYNTHESIS | VIBRANT HOLDINGS, LLC (US) | 2017-07-06 | — | — | WO | disclosed |
| US-9687481-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688691-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-9688691-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| CN-106661009-A | Anti-enterovirus 71 thiadiazolidine derivative | 江苏康缘药业股份有限公司 | 2017-05-10 | — | — | CN | disclosed |
| WO-2017071569-A1 | SALT FORM AND CRYSTAL FORM OF 1,2,5—THIADIAZOLIDIN-1,1-DIOXIDE, PREPARATION METHOD THEREOF AND INTERMEDIATE | 江苏康缘药业股份有限公司 | 2017-05-04 | — | — | WO | disclosed |
| EP-2576507-B1 | HEXAFLUOROISOPROPYL CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2017-04-05 | — | — | EP | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| EP-3138840-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion Pharmaceutical Co., Ltd. (CN) | 2017-03-08 | — | — | EP | disclosed |
| EP-3138840-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion Pharmaceutical Co., Ltd. (CN) | 2017-03-08 | — | — | EP | disclosed |
| WO-2017029631-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017025914-A1 | 5-(N-FUSED TRICYCLIC ARYL TETRAHYDROISOQUINOLIN-6-YL) PYRIDIN-3- YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017025917-A1 | 5-(N-BENZYL TETRAHYDROISOQUINOLIN-6-YL) PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017025913-A1 | IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017025864-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017025916-A1 | 5-(N-[6,5]-FUSED BICYCLIC ARYL TETRAHYDROISOQUINOLIN-6-YL) PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017025915-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-16 | — | — | WO | disclosed |
| EP-2326656-B1 | RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END | CHEMGENES CORP (US) | 2017-01-25 | — | — | EP | disclosed |
| WO-2017006260-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-01-12 | — | — | WO | disclosed |
| WO-2017006261-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-01-12 | — | — | WO | disclosed |
| WO-2017006281-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-01-12 | — | — | WO | disclosed |
| WO-2017006280-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-01-12 | — | — | WO | disclosed |
| US-9540417-B2 | Compositions and methods for treating ischemia and ischemia-reperfusion injury | ISCHEMIX LLC (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160288080-A1 | Substrates, Systems, and Methods for Array Synthesis and Biomolecular Analysis | VIBRANT HOLDINGS LLC (CA) | 2016-10-06 | — | — | US | disclosed |
| US-20160264622-A1 | Compositions And Methods For Treating Ischemia And Ischemia-Reperfusion Injury | ISCHEMIX LLC | 2016-09-15 | — | — | US | disclosed |
| EP-1939687-B1 | Polymerizable composition and lithographic printing plate precursor | FUJIFILM CORP (JP) | 2016-09-14 | — | — | EP | disclosed |
| CN-104250239-B | The polycyclic carboxylic acid derivates of fragrance | 山东轩竹医药科技有限公司 | 2016-09-07 | — | — | CN | disclosed |
| US-20160200732-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2016-07-14 | — | — | US | disclosed |
| US-20160200732-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2016-07-14 | — | — | US | disclosed |
| US-20160200732-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2016-07-14 | — | — | US | disclosed |
| EP-2274287-B1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-9265772-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265772-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265772-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| CN-102958935-B | Large ring integrase inhibitor | JANSSEN R&D IRELAND (IE) | 2015-12-09 | — | — | CN | disclosed |
| US-20150335632-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2015-11-26 | — | — | US | disclosed |
| CN-105085512-A | Enteric virus 71 (EV71)-resistant thiadiazolidine derivatives | NANJING MINGDE NEW DRUG RES AND DEV CO LTD | 2015-11-25 | — | — | CN | disclosed |
| CN-105085512-A | Enteric virus 71 (EV71)-resistant thiadiazolidine derivatives | NANJING MINGDE NEW DRUG RES AND DEV CO LTD | 2015-11-25 | — | — | CN | disclosed |
| WO-2015165340-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | 南京明德新药研发股份有限公司 | 2015-11-05 | — | — | WO | disclosed |
| US-9163012-B2 | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| EP-2920272-A2 | SUBSTRATES, SYSTEMS, AND METHODS FOR ARRAY SYNTHESIS AND BIOMOLECULAR ANALYSIS | Vibrant Holdings, LLC (US) | 2015-09-23 | — | — | EP | disclosed |
| US-9079861-B2 | Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| CN-104640856-A | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS INC | 2015-05-20 | — | — | CN | disclosed |
| EP-2220052-B1 | CYCLIC UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2015-03-25 | — | — | EP | disclosed |
| EP-2493305-B1 | 2-AMINOINDOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA | GENZYME CORP (US) | 2015-03-25 | — | — | EP | disclosed |
| US-8980926-B2 | 2-aminoindole compounds and methods for the treatment of malaria | GENZYME CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-8927534-B2 | Compounds for the inhibition of integrins and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| CN-104250239-A | Aromatic polycyclic carboxylic acid derivative | KBP BIOSCIENCES CO LTD | 2014-12-31 | — | — | CN | disclosed |
| US-8865684-B2 | Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2014-10-21 | — | — | US | disclosed |
| US-20140274917-A1 | Compositions and Methods for Treating Ischemia and Ischemia-Reperfusion Injury | ISCHEMIX LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-8835418-B2 | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2014-09-16 | — | — | US | disclosed |
| US-20140256714-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
| US-8828985-B2 | Carbamate and urea inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8796256-B2 | Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-α modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-05 | — | — | US | disclosed |
| WO-2014116836-A2 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEXA THERAPEUTICS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
| US-8772250-B2 | Compositions and methods for treating ischemia and ischemia-reperfusion injury | Ischemix, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-8771924-B2 | Polymerizable composition, lithographic printing plate precursor and lithographic printing method | FUJIFILM CORPORATION (JP) | 2014-07-08 | — | — | US | disclosed |
| US-8772249-B2 | Compositions and methods for treating ischemia and ischemia-reperfusion injury | Ischemix, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| WO-2014100425-A1 | PERI-CARBINOLS | ALDEXA THERAPEUTICS, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-8748444-B2 | Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| WO-2014078606-A2 | SUBSTRATES, SYSTEMS, AND METHODS FOR ARRAY SYNTHESIS AND BIOMOLECULAR ANALYSIS | VIBRANT HOLDINGS, LLC (US) | 2014-05-22 | — | — | WO | disclosed |
| US-8716293-B2 | Macrocyclic integrase inhibitors | JANSSEN R&D IRELAND (IE) | 2014-05-06 | — | — | US | disclosed |
| US-8716293-B2 | Macrocyclic integrase inhibitors | JANSSEN R&D IRELAND (IE) | 2014-05-06 | — | — | US | disclosed |
| US-8716293-B2 | Macrocyclic integrase inhibitors | JANSSEN R&D IRELAND (IE) | 2014-05-06 | — | — | US | disclosed |
| EP-2429519-B1 | COMPOSITIONS AND METHODS FOR TREATING ISCHEMIA AND ISCHEMIA-REPERFUSION INJURY | ISCHEMIX LLC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8703811-B2 | Small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase | GENZYME CORPORATION (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2552923-B1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R & D IRELAND (IE) | 2014-03-26 | — | — | EP | disclosed |
| US-8680281-B2 | Lactam inhibitors of 11-β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8629156-B2 | Tryptophan hydroxylase inhibitors | LEXICON PHARMACEUTICALS, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130331360-A1 | MORPHOLIN-4-IUM 4 METHOXYPHENYL (MORPHOLINO) PHOSPHINODITHIOATE (GYY4137) AS A NOVEL VASODILATOR AGENT | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-12-12 | — | — | US | disclosed |
| EP-2669288-A1 | New monosaccharide derivatives and biological applications thereof | LABORATOIRE BIODIM (FR) | 2013-12-04 | — | — | EP | disclosed |
| US-8598160-B2 | Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8592409-B2 | Cyclic carbazate and semicarbazide inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | Synchronicity Pharma, Inc. | 2013-11-14 | — | — | US | disclosed |
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | Synchronicity Pharma, Inc. | 2013-11-14 | — | — | US | disclosed |
| US-20130303524-A1 | Carbazole-Containing Sulfonamides as Cryptochrome Modulators | Synchronicity Pharma, Inc. | 2013-11-14 | — | — | US | disclosed |
| US-8541396-B2 | Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-09-24 | — | — | US | disclosed |
| US-8541569-B2 | Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA | CHEMGENES CORPORATION (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130245051-A1 | CYCLIC UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244994-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | CLAREMON DAVID A (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130165422-A1 | HEXAFLUOROISOPROPYL CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2013-06-27 | — | — | US | disclosed |
| US-8440658-B2 | Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8399504-B2 | Carbamate and urea inhibitors of 11Beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED | 2013-02-28 | — | — | US | disclosed |
| EP-2560982-A2 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION | Chemgenes Corporation (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-02-07 | — | — | US | disclosed |
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-02-07 | — | — | US | disclosed |
| US-20130035341-A1 | MACROCYCLIC INTEGRASE INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-02-07 | — | — | US | disclosed |
| EP-2552923-A1 | MACROCYCLIC INTEGRASE INHIBITORS | Janssen R&D Ireland (IE) | 2013-02-06 | — | — | EP | disclosed |
| EP-2536711-A1 | 5-HT RECEPTOR MODULATORS | Cambridge Enterprise Limited (GB) | 2012-12-26 | — | — | EP | disclosed |
| EP-2252601-B1 | CYCLIC CARBAZATE AND SEMICARBAZIDE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2012154126-A1 | A SLOW-RELEASING HYDROGEN SULPHIDE DONOR IN A METHOD FOR THE TREATMENT OF CANCER | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012142457-A2 | MACROLACTAM COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA | THE BROAD INSTITUTE, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| EP-1984344-B1 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-09-13 | — | — | US | disclosed |
| US-20120190659-A1 | ANGIOGENESIS INHIBITORS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120157484-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS | TERSERA THERAPEUTICS LLC | 2012-06-21 | — | — | US | disclosed |
| US-8202857-B2 | 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20120135932-A1 | Compositions And Methods For Treating Ischemia And Ischemia-Reperfusion Injury | ISCHEMIX LLC | 2012-05-31 | — | — | US | disclosed |
| WO-2011162514-A3 | METHOD FOR PREPARING [1,2,3]-OXATHIAZOLIDINE-2,2-DIOXIDE OR [1,2,5]-THIADIAZOLIDINE-1,1-DIOXIDE DERIVATIVES | 한국화학연구원 (KR) | 2012-05-03 | — | — | WO | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2429519-A1 | COMPOSITIONS AND METHODS FOR TREATING ISCHEMIA AND ISCHEMIA-REPERFUSION INJURY | Ischemix LLC (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2421882-A2 | ANGIOGENESIS INHIBITORS | President and Fellows of Harvard College (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2011162514-A2 | METHOD FOR PREPARING [1,2,3]-OXATHIAZOLIDINE-2,2-DIOXIDE OR [1,2,5]-THIADIAZOLIDINE-1,1-DIOXIDE DERIVATIVES | 한국화학연구원 (KR) | 2011-12-29 | — | — | WO | disclosed |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | US | disclosed |
| US-8063057-B2 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2386547-A1 | Multicyclic amino acid derivatives and methods of their use | Lexicon Pharmaceuticals, Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110263582-A1 | CYCLIC UREA INHIBITORS OF 11 B-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-8039086-B2 | Bonding material, process for producing the same, and honeycomb structure made with the same | NGK INSULATORS, LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2011121105-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011103468-A2 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION | CHEMGENES CORPORATION (US) | 2011-08-25 | — | — | WO | disclosed |
| US-8003642-B2 | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| WO-2011098776-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-08-18 | — | — | WO | disclosed |
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | SB PHARMCO PUERTO RICO INC | 2011-07-14 | — | — | US | disclosed |
| EP-2341049-A1 | 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as PTPASE 1B inhibitors | Novartis AG (CH) | 2011-07-06 | — | — | EP | disclosed |
| US-20110160294-A1 | COMPOSITIONS AND METHODS FOR TREATING ISCHEMIA AND ISCHEMIA-REPERFUSION INJURY | ISCHEMIX LLC (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110137010-A1 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, EFFICIENT RNA SYNTHESIS AND CONVENIENT INTRODUCTION OF 3'-END LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA | CHEMGENES CORPORATION (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110130381-A1 | SMALL MOLECULE INHIBITORS OF PLASMODIUM FALCIPARUM DIHYDROOROTATE DEHYDROGENASE | GENZYME CORPORATION | 2011-06-02 | — | — | US | disclosed |
| EP-2326656-A2 | RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END | Chemgenes Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20110112062-A1 | Carbamate And Urea Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC | 2011-05-12 | — | — | US | disclosed |
| US-20110112082-A1 | CYCLIC CARBAZATE AND SEMICARBAZIDE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110105504-A1 | Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1 | Vitae Pharmaceuticals ,Inc. | 2011-05-05 | — | — | US | disclosed |
| US-20110098320-A1 | Lactam Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. | 2011-04-28 | — | — | US | disclosed |
| US-7928067-B2 | Compositions and methods for treating ischemia and ischemia-reperfusion injury | ISCHEMIX LLC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20110071139-A1 | Cycloalkyl Lactame Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110053943-A1 | CARBAMATE AND UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110046105-A1 | Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
| EP-2274287-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Vitae Pharmaceuticals, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20100324045-A1 | CYCLIC UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
| EP-2252601-A1 | CYCLIC CARBAZATE AND SEMICARBAZIDE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010132657-A1 | COMPOSITIONS AND METHODS FOR TREATING ISCHEMIA AND ISCHEMIA-REPERFUSION INJURY | ISCHEMIX LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292313-A1 | COMPOSITIONS AND METHODS FOR TREATING ISCHEMIA AND ISCHEMIA-REPERFUSION INJURY | ISCHEMIX LLC | 2010-11-18 | — | — | US | disclosed |
| US-20100280054-A1 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | TERSERA THERAPEUTICS LLC | 2010-11-04 | — | — | US | disclosed |
| US-20100273743-A1 | MORPHOLIN-4-IUM 4 METHOXYPHENYL (MORPHOLINO) PHOSPHINODITHIOATE (GYY4137) AS A NOVEL VASODILATOR AGENT | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2010-10-28 | — | — | US | disclosed |
| WO-2010123545-A2 | ANGIOGENESIS INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-10-28 | — | — | WO | disclosed |
| US-7759492-B2 | Enantioselective synthesis of 13-oxotricyclo[8.2.1.0.3,8] trideca-3(8),4,6-triene-5-carboxylates | MERCK SHARP & DOHME LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7723345-B2 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2186813-A1 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SmithKline Beecham (Cork) Limited (IE) | 2010-05-19 | — | — | EP | disclosed |
| WO-2010027512-A9 | RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END | CHEMGENES CORPORATION (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010027512-A2 | RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END | CHEMGENES CORPORATION (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20100041637-A1 | 1,3-Oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| EP-2121598-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009137081-A2 | SMALL MOLECULE INHIBITORS OF PLASMODIUM FALCIPARUM DIHYDROOROTATE DEHYDROGENASE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009117109-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009094169-A1 | CYCLIC CARBAZATE AND SEMICARBAZIDE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20090131403-A1 | NITROGENATED HETEROCYCLIC DERIVATIVE , AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| CN-101434604-A | Condensed n-heterocyclic compounds and their use as CRF receptor antagonists | SB PHARMCO INC (IE) | 2009-05-20 | — | — | CN | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20090104116-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20080312444-A1 | Process for Preparing Bicyclic Compounds | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2008-12-18 | — | — | US | disclosed |
| EP-1995246-A1 | NITROGENATED HETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1984344-A2 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1979342-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | Jerini AG (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-7427630-B2 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SB PHARMACO PUERTO RICO INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20080199804-A1 | Including free radical binder polymer containing functional group having dipole moment of 3.8 debye; laser computer controlled direct plate making without alkali development; sensitivity, printing durability | FUJIFILM CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080199804-A1 | Including free radical binder polymer containing functional group having dipole moment of 3.8 debye; laser computer controlled direct plate making without alkali development; sensitivity, printing durability | FUJIFILM CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| CN-101218239-A | Process for preparing bicyclic compounds | SB PHARMCO INC (PR) | 2008-07-09 | — | — | CN | disclosed |
| WO-2008076754-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2008-06-26 | — | — | WO | disclosed |
| US-20080139576-A1 | 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives | NOVARTIS AG (CH) | 2008-06-12 | — | — | US | disclosed |
| WO-2007129195-A2 | 4-PYRIMIDINE-5-AMINO-PYRAZOLE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| CN-101072564-A | Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof | ENCYSIVE PHARMACEUTICALS INC (US) | 2007-11-14 | — | — | CN | disclosed |
| US-7291635-B2 | 5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives | NOVARTIS AG (CH) | 2007-11-06 | — | — | US | disclosed |
| US-20070244329-A1 | Enantioselective Synthesis of 13-Oxotricyclo[8.2.1.0. 3,8] Trideca-3(8),4,6-Triene-5-Carboxylates | MERCK SHARP & DOHME LIMITED (GB) | 2007-10-18 | — | — | US | disclosed |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | TERSERA THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2007088041-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089335-A2 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | LEXICON PHARMACEUTICAL INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| EP-1781591-A1 | ENANTIOSELECTIVE SYNTHESIS OF 13-OXOTRICYCLO[8.2.1.0 3,8]TRIDECA-3(8),4,6-TRIENE-5-CARBOXYLATES | MERCK SHARP & DOHME LTD. (GB) | 2007-05-09 | — | — | EP | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070021429-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-01-25 | — | — | US | disclosed |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | NEUROCRINE BIOSCIENCES, INC. | 2007-01-04 | — | — | US | disclosed |
| CN-1805958-A | fused N-heterocyclic compounds and their use as CRF receptor antagonists | SB PHARMCO INC (PR) | 2006-07-19 | — | — | CN | disclosed |
| EP-1670757-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1669060-A1 | New sulfamide derivatives and their cosmetic use | L'OREAL (FR) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006018663-A1 | ENANTIOSELECTIVE SYNTHESIS OF 13-OXOTRICYCLO[8.2.1.0 3,8]TRIDECA-3(8),4,6-TRIENE-5-CARBOXYLATES | MERCK SHARP & DOHME LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
| EP-1611133-A1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC. CSC, The United States Corporation Company (PR) | 2006-01-04 | — | — | EP | disclosed |
| CN-1646508-A | 5-substituted 1, 1-dioxo-1, 2, 5-thiadiazolidin-3-one derivatives as PTP-1B inhibitors | NOVARTIS AG (CH) | 2005-07-27 | — | — | CN | disclosed |
| WO-2005040110-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20050090502-A1 | Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents | NOVARTIS AG (CH) | 2005-04-28 | — | — | US | disclosed |
| US-6872738-B1 | Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2005-03-29 | — | — | US | disclosed |
| EP-1492780-A1 | 5-SUBSTITUTED 1,1-DIOXO-[1,2,5]THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | Novartis AG (CH) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004094420-A1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | COPPOLA GARY MARK | 2004-02-05 | — | — | US | disclosed |
| WO-2003082841-A1 | 5-SUBSTITUTED 1,1-DIOXO-`1,2,5!THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | NOVARTIS AG (CH) | 2003-10-09 | — | — | WO | disclosed |
| EP-1192132-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000076971-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-0501568-B1 | Substituted cyclic sulphamide derivatives | MERCK SHARP & DOHME (GB) | 1997-08-20 | — | — | EP | disclosed |
| US-5194440-A | Treatment for migraine; selective agonist | MERCK SHARP & DOHME LTD. (GB) | 1993-03-16 | — | — | US | disclosed |
| EP-0501568-A1 | Substituted cyclic sulphamide derivatives | MERCK SHARP & DOHME LTD. (GB) | 1992-09-02 | — | — | EP | disclosed |
| EP-0135318-A1 | Quinazoline cardiac stimulants | Pfizer Limited (GB) | 1985-03-27 | — | — | EP | disclosed |
| EP-0135318-A1 | Quinazoline cardiac stimulants | Pfizer Limited (GB) | 1985-03-27 | — | — | EP | disclosed |